Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare ...
Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction treatment significantly improved MRD negativity benefit and pro...
Nelipak® Corporation (“Nelipak®”), a leading global provider of healthcare packaging solutions for medical device, diagnostic, pharma...
4TEEN4 Pharmaceuticals GmbH announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal anti...
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients, has launched POLYOX™ Extended Stability (ES) packaging, a custo...
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancemen...
Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NG...
HMNC Brain Health (“HMNC”), a global precision psychiatry biopharmaceutical company, in collaboration with Spruce Biosciences, Inc. (OTCQB: S...
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology. The mini...
Corteria Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of transformative therapies for heart failure and obesity, ...
Sanofi announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a p...
Adalvo was founded in 2018 by Aztiq and is one of the leading business-to-business pharmaceutical companies in Europe EQT will support Adalvo’s ...
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced that the European Commission (EC) granted conditi...
Qualigen Therapeutics, Inc. is announcing an update on patents granted in the first six months of 2025. The patent is Titled “Substitued Naphthalen...
© 2025 Biopharma Boardroom. All Rights Reserved.
